Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2016

01-10-2016 | Editorial

Prevention of the Paracentesis-Induced Circulatory Dysfunction (PICD) in Cirrhosis: Is the SPA Treatment Worthwhile?

Author: John Carl Hoefs

Published in: Digestive Diseases and Sciences | Issue 10/2016

Login to get access

Excerpt

The older leading concept concerning ascites formation postulates an imbalance of oncotic and hydrostatic forces, with portal pressure pushing fluid into the peritoneal cavity opposed by the serum colloid osmotic pressure generated by albumin. When hydrostatic exceed oncotic forces, the abdominal cavity fills with fluid until a counterbalancing increase in abdominal pressure prevents further ascites formation. Furthermore, patients with ascites are almost perfectly separated from those without ascites on the basis of portal pressure (relative to the cardiac pressure) and serum albumin concentration [1] seeming to support this concept. According to this model, decreased intra-abdominal pressure due to fluid removal by paracentesis promotes fluid movement into the peritoneal cavity at the expense of the intravascular compartment, potentially resulting in catastrophic hypotension and renal failure. Since these events were thought to occur soon after paracentesis, the prevailing recommendation was for <2 L to be removed at any one time. Harmful effects from paracentesis were considered likely despite a large global clinical experience that had not identified a high incidence of hypotension or renal failure due to a common and routine clinical procedure. …
Literature
1.
go back to reference Cerrick GR, Kerr DNA, Read AE, Sherlock S. Colloid osmotic pressure and hydrostatic pressure relationships in the formation of ascites in hepatic cirrhosis. Clin Sci. 1960;19:361–371. Cerrick GR, Kerr DNA, Read AE, Sherlock S. Colloid osmotic pressure and hydrostatic pressure relationships in the formation of ascites in hepatic cirrhosis. Clin Sci. 1960;19:361–371.
2.
go back to reference Hoefs JC. Serum protein concentration and portal pressure determines the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med. 1983;102:260–273.PubMed Hoefs JC. Serum protein concentration and portal pressure determines the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med. 1983;102:260–273.PubMed
3.
go back to reference Hoefs JC. The mechanism of ascitic fluid protein concentration increase during diuresis in patients with chronic liver disease. Am J Gastroenterol. 1981;76:423–431.PubMed Hoefs JC. The mechanism of ascitic fluid protein concentration increase during diuresis in patients with chronic liver disease. Am J Gastroenterol. 1981;76:423–431.PubMed
4.
go back to reference Pare P, Talbot J, Hoefs JC. Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology. 1984;85:240–244. Pare P, Talbot J, Hoefs JC. Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology. 1984;85:240–244.
5.
go back to reference Hoefs JC. Globulin correction of albumin gradient: correlation with measured serum to ascites colloid osmotic pressure gradients. Hepatology. 1992;16:396–403.CrossRefPubMed Hoefs JC. Globulin correction of albumin gradient: correlation with measured serum to ascites colloid osmotic pressure gradients. Hepatology. 1992;16:396–403.CrossRefPubMed
6.
go back to reference Reynolds TB. Therapeutic paracentesis: have we come full circle? Gastroenterology. 1987;93:386–388.CrossRefPubMed Reynolds TB. Therapeutic paracentesis: have we come full circle? Gastroenterology. 1987;93:386–388.CrossRefPubMed
7.
go back to reference Gines P, Arroyo V, Quintero E, et al. Comparison between paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of randomized study. Gastroenterology. 1987;93:234–241.CrossRefPubMed Gines P, Arroyo V, Quintero E, et al. Comparison between paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of randomized study. Gastroenterology. 1987;93:234–241.CrossRefPubMed
8.
go back to reference Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113:579–586.CrossRefPubMed Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113:579–586.CrossRefPubMed
9.
go back to reference Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493–1502.CrossRefPubMed Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493–1502.CrossRefPubMed
10.
go back to reference Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409.CrossRefPubMed Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409.CrossRefPubMed
11.
go back to reference Tan HK, James PD, Wong F. Albumin may prevent the morbidity of paracentesis-induced circulatory dysfunction in cirrhosis and refractory ascites: a pilot study. Dig Dis Sci. (Epub ahead of print.) doi:10.1007/s10620-016-4140-3. Tan HK, James PD, Wong F. Albumin may prevent the morbidity of paracentesis-induced circulatory dysfunction in cirrhosis and refractory ascites: a pilot study. Dig Dis Sci. (Epub ahead of print.) doi:10.​1007/​s10620-016-4140-3.
12.
go back to reference Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–2107.CrossRefPubMed Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–2107.CrossRefPubMed
13.
go back to reference Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55:1172.CrossRefPubMed Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55:1172.CrossRefPubMed
14.
go back to reference Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: across-over study. J Hepatol. 2011;55:794–797.CrossRefPubMed Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: across-over study. J Hepatol. 2011;55:794–797.CrossRefPubMed
15.
go back to reference Peltekian KM, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol. 1997;92:394–399.PubMed Peltekian KM, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol. 1997;92:394–399.PubMed
Metadata
Title
Prevention of the Paracentesis-Induced Circulatory Dysfunction (PICD) in Cirrhosis: Is the SPA Treatment Worthwhile?
Author
John Carl Hoefs
Publication date
01-10-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4248-5

Other articles of this Issue 10/2016

Digestive Diseases and Sciences 10/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.